Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors.
about
Multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphism: from discovery to clinical applicationRole of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update.Potentially functional genetic variants in KDR gene as prognostic markers in patients with resected colorectal cancer.
P2860
Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Pharmacogenetics of telatinib, ...... in patients with solid tumors.
@ast
Pharmacogenetics of telatinib, ...... in patients with solid tumors.
@en
Pharmacogenetics of telatinib, ...... in patients with solid tumors.
@nl
type
label
Pharmacogenetics of telatinib, ...... in patients with solid tumors.
@ast
Pharmacogenetics of telatinib, ...... in patients with solid tumors.
@en
Pharmacogenetics of telatinib, ...... in patients with solid tumors.
@nl
prefLabel
Pharmacogenetics of telatinib, ...... in patients with solid tumors.
@ast
Pharmacogenetics of telatinib, ...... in patients with solid tumors.
@en
Pharmacogenetics of telatinib, ...... in patients with solid tumors.
@nl
P2093
P2860
P1476
Pharmacogenetics of telatinib, ...... in patients with solid tumors.
@en
P2093
Ferry A L M Eskens
Hans Gelderblom
Johan W R Nortier
Judith Wessels
Natasja de Bont
Neeltje Steeghs
P2860
P2888
P304
P356
10.1007/S10637-009-9347-0
P577
2009-11-19T00:00:00Z
P5875
P6179
1012626116